GlassScriptPhysician profile
Lori L Pace
NPI 1417053190
$2,699.22
in general payments reported to CMS, 2019-2025
32 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $712 · 2022: $725 · 2023: $690 · 2024: $223 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $579.44 | 2021-2024 | Wegovy |
| Abbvie INC. | $427.24 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $197.28 | 2021-2025 | |
| Hologic Sales and Service, LLC | $124.14 | 2022-2025 | Myosure Tissue Removal Device, Novasure, Coolseal Generator |
| Sumitomo Pharma America, INC. | $112.21 | 2023-2025 | Gemtesa |
| Bausch Health US, LLC | $108.37 | 2021-2022 | |
| Sage Therapeutics, LLC | $98.20 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $92.41 | 2023-2024 | Accrufer |
| Astellas Pharma US INC | $87.25 | 2023-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $85.56 | 2022 | |
| Pfizer INC. | $79.13 | 2021-2023 | |
| Agile Therapeutics, INC. | $63.59 | 2021-2022 | |
| Urovant Sciences INC | $60.16 | 2022 | |
| Organon LLC | $54.85 | 2022-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $54.60 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $54.35 | 2021-2022 | |
| Aspira Women'S Health INC | $53.90 | 2021 | |
| Galt Pharmaceuticals, LLC | $46.83 | 2023 | Orphengesic Forte |
| Lilly USA, LLC | $41.50 | 2022-2023 | Emgality, Zepbound |
| Exeltis, USA INC. | $39.56 | 2021-2023 | Slynd |
| Evofem Biosciences, INC. | $30.25 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $26.96 | 2021 | |
| Roche Diagnostics Corporation | $21.29 | 2021 | |
| Virtus Pharmaceuticals LLC | $20.46 | 2021 | |
| Daiichi Sankyo INC. | $19.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.25 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.66 | 2025 | Qelbree |
| Exact Sciences Corporation | $18.66 | 2025 | Cologuard Collection Kit |
| Baxter Healthcare | $17.26 | 2024 | Perclot |
| Solventum Corporation | $17.06 | 2025 | Prevena |
| Smith+Nephew, INC. | $15.31 | 2022 | |
| Therapeuticsmd, INC. | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.